| --- | --- | |-------------------------------------------------------------------------------------------|-------| | | | | | | | The data-driven R&D Autobahn to Cures Evotec SE, Full-year 2020 results, 25 March 2021 | | and and the see and a be a comment of the subseries of Forward looking statement | --- | |--------------------------------------------------------------------------------------------| | | | Information set forth in this presentation contains forward-looking statements, which | | involve a n ...

Evotec SE (OTCPK:EVOTF) Q4 2020 Earnings Conference Call March 25, 2021 9:00 AM ET Company Participants Werner Lanthaler - CEO Enno Spillner - CFO Cord Dohrmann - Chief Scientific Officer Craig Johnstone - COO Conference Call Participants Joseph Hedden - Rx Securities Limited Falko Friedrichs - Deutsche Bank Charles Weston - RBC Capital Markets Naresh Chouhan - Intrinsic Health Advisors Victoria English - MedNous Mohamad Vaseghi - Frankfurt Main Research Christian Ehmann - Warburg Research Operator Dear lad ...

Evotec SE (OTCPK:EVOTF) Q3 2020 Earnings Conference Call November 12, 2020 8:00 AM ET Company Participants Werner Lanthaler - CEO Enno Spillner - CFO Craig Johnstone - COO Cord Dohrmann - Chief Scientific Officer Conference Call Participants Igor Kim - Bankhaus Lampe Nick Nieland - Citigroup Charles Weston - RBC Capital Markets Bruno Bulic - Baader-Helvea Joseph Hedden - Rx Securities Limited Naresh Chouhan - Intrinsic Health Advisors Kieron Banerjee - goetzpartners securities Victoria English - Evernow Pub ...

Financial Performance (9M 2020) - Group revenues increased by 12% to €360.4 million compared to €321.4 million in 9M 2019 [11] - Like-for-like growth of the base business, adjusted for portfolio and FX effects, was up by 19% [11] - Adjusted Group EBITDA was €76.9 million, compared to €93.2 million in 9M 2019, but showed a strong upswing in Q3 [11] - Increased investment in unpartnered R&D expenses to €33.4 million, up from €25.7 million in 9M 2019 [11] - R&D expenses reached €46.1 million, a 12% increase from €41.3 million in 9M 2019 [17] Q3 2020 Highlights - Revenue growth was driven by strong performance in the base business, with improved revenues from milestones, upfronts, and licenses [21] - Revenues from contracts with customers reached €129.4 million in Q3 2020, compared to €114.3 million in Q3 2019 [21] Guidance 2020 - Total Group revenues are expected to range from €440 million to €480 million, based on constant 2019 exchange rates [11, 48] - Adjusted Group EBITDA is expected to be in the range of €100 million to €120 million [11, 48] - Unpartnered Group R&D expenses are projected to be approximately €45 million [11, 48] Strategic Investments and Partnerships - Mubadala Investment Company made a €200 million investment, translating into 5.6% of the total new number of 163.5 million Evotec shares [15]

U MECCABCHNEVCKJIDTO Evotec Partnered Drug Discovery and Development Evotec SE, Company Presentation, H.C. Wainwright 22nd Annual Global Investment Conference, 14 September 2020 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor g ...

U PECEADCHNEVERJIUTS Evotec Partnered Drug Discovery and Development Evotec SE, Company Presentation, Morgan Stanley 18th Annual Global Healthcare Conference, 16 September 2020 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor gu ...

Evotec SE (OTCPK:EVOTF) Q2 2020 Earnings Conference Call August 12, 2020 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Cord Dohrmann - Chief Scientific Officer Conference Call Participants Joseph Hedden - Rx Securities Igor Kim - Bankhaus Lampe Falko Friedrichs - Deutsche Bank AG Victoria English - Evernow Publishing Ltd Boobalan Pachaiyappan - H.C. Wainwright & Co., LLC Naresh Chouhan - Intron Hea ...

evotec #RESEARCHNEVERSTOPS "We are Autobahn" OM MERCIA PRODUCT PRECLINICAL ADRUG DISCOVERY DISCOVERY PLATFORM T CELL & GENE "3" Evotec SE, H1 2020 Interim Report, 12 August 2020 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor g ...

Evotec SE (OTCPK:EVOTF) Q1 2020 Earnings Conference Call May 14, 2020 8:00 AM ET Company Participants Werner Lanthaler – Chief Executive Officer Enno Spillner – Chief Financial Officer Craig Johnstone – Chief Operating Officer Cord Dohrmann – Chief Scientific Officer Conference Call Participants Boobalan Pachaiyappan – H.C. Wainwright Victoria English – Evernow Publishing Ltd Naresh Chouhan – Intron Health Joseph Hedden – Rx Securities Werner Lanthaler Good afternoon. This is Werner speaking from Hamburg. G ...

Evotec SE (OTCPK:EVOTF) Q4 2019 Earnings Conference Call March 26, 2020 9:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Cord Dohrmann - Chief Scientific Officer Conference Call Participants Joseph Hedden - Rx Securities Naresh Chouhan - Intron Health Falko Friedrichs - Deutsche Bank Victoria English - Evernow Publishing Ltd. Patrick Trucchio - Berenberg Capital Markets LLC Boobalan Pachaiyappan - H.C ...